Autres langues DiaMedica Therapeutics Inc.

Actions

DMAC

CA25253X2077

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 26/04/2024			Varia. 5j.	Varia. 1 janv.
2,57 ^USD	+1,58 %		+7,53 %	-9,51 %

17/04	DiaMedica Therapeutics Inc. annonce le dosage du premier patient dans le cadre de la relance de son essai pivot de phase /3 ReMEDy2 sur le DM199 pour le traitement de l'accident vasculaire cérébral ischémique aigu	CI
10/04	DiaMedica Therapeutics Inc. annonce des changements au sein de sa direction	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

DiaMedica Therapeutics Launches Late-Stage Trial of Potential Stroke Treatment	17/04
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke	17/04
DiaMedica Therapeutics Inc. Announces First Patient Dosed in Relaunch of Its Pivotal Phase /3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke	17/04
DiaMedica Therapeutics Inc. Announces Executive Changes	10/04
DiaMedica Therapeutics Files $100 Million Mixed Shelf	21/03
DiaMedica Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19/03
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results	19/03
DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference	29/01
DiaMedica Therapeutics Names Lorianne Masuoka as Chief Medical Officer	22/01
DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer	22/01
DiaMedica Therapeutics Inc. Appoints Dr. Lorianne Masuoka as Chief Medical Officer	22/01
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results	13/11
DiaMedica Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
DiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023	09/11
DiaMedica Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update November 14, 2023	06/11
Top Premarket Gainers	25/10/23
DiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology Officer	12/09/23
DiaMedica Therapeutics Inc. Announces the Appointment of Ambarish Shah as Chief Technology Officer	12/09/23
DiaMedica Therapeutics to Participate at Lake Street's 7th Annual Best Ideas Growth Conference	07/09/23
DiaMedica Therapeutics to Participate at Lake Street’s 7th Annual Best Ideas Growth Conference	06/09/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues DiaMedica Therapeutics Inc.

Actions

DMAC

CA25253X2077

Autres langues

Filtres